This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
05 December 2008
In the version of this article initially published, on p. 958, righthand column, line 2, it was incorrectly stated that Rituxan is used for treating multiple sclerosis: “Rituxan (rituximab), a B cell–depleting biologic for treating rheumatoid arthritis and multiple sclerosis, has shifted the focus towards B cells.” The sentence should have read, “Rituxan (rituximab), a B cell–depleting biologic for treating rheumatoid arthritis and non-Hodgkin’s lymphoma, has shifted the focus towards B cells.” The error has been corrected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Melton, L., Coombs, A. Actemra poised to launch IL-6 inhibitors. Nat Biotechnol 26, 957–958 (2008). https://doi.org/10.1038/nbt0908-957
Issue Date:
DOI: https://doi.org/10.1038/nbt0908-957
This article is cited by
-
Mendelian Randomization Analyses for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection
Cardiovascular Drugs and Therapy (2016)
-
Genetic Evidence for an Essential Role of Neuronally Expressed IL-6 Signal Transducer gp130 in the Induction and Maintenance of Experimentally Induced Mechanical Hypersensitivity in vivo and in vitro
Molecular Pain (2011)
-
Erratum: Actemra poised to launch IL-6 inhibitors
Nature Biotechnology (2008)